-
2022-501254-10-00
5
2018-08-24
Advanced tumors
-
2023-504880-18-00
9
2018-04-18
Neuroblastoma (NBL)
-
2024-516110-38-00
5
2018-03-06
Hepatoblastoma and Hepatocellular Carcinoma
-
2024-518578-15-00
5
2018-02-05
Is to demonstrate a non inferior efficacy of azithromycin and so the p
-
2023-505625-14-00
7
2017-01-31
Relapsed/refractory B-cell non-Hodgkin’s lymphoma (r/r NHL)
-
2024-515432-71-00
5
2016-09-13
gastrointestinal stromal tumor
-
2024-514791-40-00
9
2016-08-03
pediatric cancer
-
2024-516725-31-00
9
2016-04-14
advanced and metastatic
-
2024-512222-28-00
10
2015-06-02
Newly diagnosed with an intracranial or spinal ependymoma (all WHO gra
-
2023-506027-29-00
5
2014-10-01
Children, adolescents and adults with newly diagnosed diffuse intrinsi
-
2024-515626-92-00
4
2013-10-18
recurrent/progressive medulloblastoma, ependymoma and atypical teratoi
-
2024-516358-23-00
5
2013-06-24
Gastric adenocarcinoma
-
2024-517275-21-00
4
2012-02-20
Retinoblastoma
-
2024-517390-24-00
5
2011-04-26
Ovarian epithelial cancer : intraperitoneal resectable relapse
-
2022-502942-29-01
9
2026-03-23
Fronto-Temporal Dementia with Progranulin Mutations (FTD-GRN)
-
2025-521970-33-00
5
2025-12-19
Pulmonary Arterial Hypertension (PAH)
-
2023-508827-10-00
4
2025-10-13
Patients with primary operable stage II, grade 2 or 3, Ki67 #20%, HR+/
-
2025-521681-10-00
4
2025-10-02
Lung Cancer
-
2024-519773-19-00
5
2025-07-31
Gastroesophageal Junction Adenocarcinoma
-
2024-517817-34-00
9
2025-06-18
Gastric Cancer
-
2024-516767-92-01
1
2025-06-17
Health Participants
-
2024-517818-15-00
9
2025-06-06
Non-Small Cell Lung Cancer
-
2024-513307-13-00
4
2025-05-26
Advanced/metastatic solid tumors including gynecological
cancers (endo
-
2024-512925-95-00
5
2025-05-16
Advanced/Metastatic Breast Cancer